Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The study location entry for Bucharest has been updated to use an alternate spelling/formatting (removing diacritics and standardizing the text). The page also reflects an updated revision/version label.
    Difference
    0.1%
    Check dated 2026-04-26T15:33:12.000Z thumbnail image
  3. Check
    27 days ago
    No Change Detected
  4. Check
    48 days ago
    Change Detected
    Summary
    Location name updated from Napoli, Campania, Italy, 80131 to Naples, Campania, Italy, 80131; page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-21T17:04:14.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.3, replacing Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-07T13:09:32.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    In Turkey, the study site list changed by removing Sarıyer and adding Yellowplace, both with postal code 34457.
    Difference
    0.0%
    Check dated 2026-02-28T06:32:35.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    Minor site revision updated from v3.4.1 to v3.4.2; no study content, eligibility criteria, or user-facing actions were changed.
    Difference
    0.0%
    Check dated 2026-02-14T04:56:31.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-06T23:27:08.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.